Grail Rallies as FDA Staff Flags No Major Concerns for Multi-Cancer Test

3-line summary

• Grail shares rallied after FDA staff flagged no major concerns for its multi-cancer test, according to Investing.com.

This summary is our own processing of the source article; see the source link below for full context.